IL-2K35C-moFA, a Long-Acting Engineered Cytokine with Decreased Interleukin 2 Receptor α Binding, Improved the Cellular Selectivity Profile and Antitumor Efficacy in a Mouse Tumor Model

SIMPLE SUMMARY: The application of IL-2 for treating cancer is limited owing to its toxicity and short half-life. Its high binding ability to IL-2 receptor α expands immunosuppressive Treg cells, which represents an undesirable toxicity in cancer immunotherapy. Moreover, its small molecular size is...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Xiaoze, Chen, Gang, Nie, Lei, Wu, Zhenhua, Wang, Xinzeng, Pan, Chenxiao, Chen, Xuchen, Zhao, Xiaobei, Zhu, Jie, He, Qiaojun, Wang, Haibin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9563011/
https://www.ncbi.nlm.nih.gov/pubmed/36230665
http://dx.doi.org/10.3390/cancers14194742

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9563011/
https://www.ncbi.nlm.nih.gov/pubmed/36230665
http://dx.doi.org/10.3390/cancers14194742

Ejemplares similares